Methods
Patients NTL ICD systems were implanted in 23 patients (see Table  1 ). All patients underwent thorough electrophysiological evaluation, including baseline electrophysiological study with programmed ventricular stimulation. Seventeen patients had doc- 
34±+10%. Procedures
All patients underwent baseline electrophysiological study. The details of the study are fully described elsewhere.' In brief, the aim of the study was to exclude supraventricular causes of sudden death and conduction tissue disease and to deliver programmed ventricular stimulation with triple extrastimuli at two sites at two drive cycle lengths. The hemodynamic significance (ie, sustained >30 seconds, associated with systolic blood pressure <80 mm Hg and syncope or presyncope, requiring overdrive pacing or DC cardioversion, or associated with deteriorating patient condition) of induced ventricular arrhythmias and the effect of overdrive pacing were also assessed. The latter was performed with a view to choosing the appropriate type of ICD (with or without the availability of antitachycardia pacing) in the event that ventricular tachycardia was still inducible and still hemodynamically significant after a trial of medical therapy.
All patients had a cardiological evaluation as part of their management, which included coronary arteriography and assessment of left ventricular function by contrast ventriculography, nuclear ventriculography, or two-dimensional echocardiography. Patients then gave informed consent to be enrolled in clinical studies (approved by the Committee on Human Research of the University of California, San Francisco) of NTL ICDs where appropriate, whereas other patients received market-approved NTL ICD systems.
For NTL ICD implantation, patients underwent general anesthesia in the EP laboratory unless it was felt that general anesthesia was unduly risky, in which case anesthetist-supervised deep sedation and local anesthesia were used instead. Patients were transported to the EP laboratory after an overnight fast, and general anesthesia was induced. Staffing of the laboratory included one anesthesiologist, two electrophysiologists, two electrophysiology nurse/technicians, and one device program coordinator. Kefsol (1 g IV) was given with induction of anesthesia. A cannula was introduced into the right or left radial artery for continuous monitoring of arterial blood pressure, and the urinary bladder was catheterized. In 17 patients, a quadripolar temporary electrode catheter was passed from the right femoral vein to the right ventricular apex for use in delivering AC for induction of ventricular fibrillation and also for use in backup intracardiac defibrillation (between the proximal two electrode poles and a large-surface-area posterior cutaneous patch), if needed. The entire torso from the chin to the pubis and from the right posterior axillary line to the left posterior axillary line laterally was thoroughly scrubbed with iodine/soap for 3 minutes, dried, and prepared with povidone-iodine solution, and the sterile field was delineated with linen and paper towels.
A 3-cm incision was made in the left or right subclavicular region, a small subcutaneous pocket fashioned, and a subclavian venous puncture made. A J guide wire was used to guide the passage of a 14F split-sheath introducer, and the transvenous lead was passed into the right atrium or to the innominate vein/superior vena cava. By use of fluoroscopic posteroanterior and oblique projections, the transvenous electrode was passed into the right ventricle and positioned at the right ventricular apex. When an Intermedics Res-Q or Medtronic Transvene system was implanted, an active fixation right ventricular electrode was used. When the CPI Endotak lead was used, fixation to the right ventricular endocardium was passive. Endocardial ECGs were recorded and analyzed for amplitude and the presence and size of injury current, and sensing and pacing characteristics were determined. When a single-pass (CPI Endotak) lead was used and the clinical trial protocol allowed it, the defibrillation threshold (DFT) was assessed by use of the lead alone. When a subcutaneous patch, or array, was required, an incision was made in the left axillary region just below and lateral to the left nipple, or the infraclavicular incision was expanded and the patch lead positioned via this incision. A flat subcutaneous plane was fashioned, with care taken to avoid accidental injury to the long thoracic nerve for axillary patch implants. A tunneling tool was used to position the three portions of the subcutaneous array around the posterolateral chest. The DFT was then assessed.
Before DFT testing, a low-energy (0.5-J) shock was administered during sinus rhythm to evaluate system integrity and measure lead impedance. Ventricular fibrillation was then induced. The lead systems were always first tested for ventricular defibrillation at an energy of approximately 20 J delivered manually by the implant testing device. If defibrillation was successful, ventricular fibrillation was reinduced, and delivered energies at approximately 5-J decrements were tested. If defibrillation failed, a rescue shock of 40 J was delivered by the implant test device or the device to be implanted (Intermedics Res-Q). At the next induction after an initial failed attempt, a 5-J increment in energy was made. No device was implanted with a defibrillation configuration yielding less than a 10-J safety margin below maximum device energy output for two defibrillation attempts. If a 10-J defibrillation safety margin failed to be achieved, a different lead/patch/array configuration was tried, and defibrillation testing was repeated.
After evaluation of DFT, a subcutaneous abdominal pocket was fashioned to the left or right of the midline, approximately midway between the level of the umbilicus and the costal margin. The lead or leads were then tunneled subcutaneously from the infraclavicular and axillary regions down to the abdominal pocket, where they were connected to the pulse generator. Ventricular fibrillation was then reinduced, detected, and defibrillated once more, automatically, with the device implanted in the abdominal pocket. After a successful automatic test, the lead system shock impedance was checked telemetrically. The wounds were then irrigated with gentamicin in 0.9% saline solution, the deep tissues were closed with interrupted 2/0 Dexon sutures and subcuticular 4/0 Maxon, or simple adhesive strips were used to simulate the skin.
Patients were managed in the coronary care unit for 24 hours, then transferred to monitored beds on the cardiology ward. If there were no contraindications after 24 to 48 hours, they returned to the EP laboratory for predischarge device testing. Ventricular fibrillation was induced by rapid overdrive pacing or AC, with the device blinded during induction if necessary, and the integrity of the system and ability to defibrillate were again determined. If the predischarge check was successful and there were no complications, patients were allowed to go home the following day.
Numerical values are given as mean±SD. A Student's t test was used to compare implant times of the earliest 10 versus the most recent 10 EP laboratory NTL ICD implants.
Results
Ventricular fibrillation could be induced in 19 patients by programmed ventricular stimulation. Four patients with a history of sudden cardiac death had easily inducible ventricular fibrillation, and 15 patients had inducible sustained monomorphic ventricular tachycardia (14 patients) or ventricular flutter (1 patient). Four patients were noninducible. Thirteen of 14 patients with ventricular tachycardia required emergent treatment by ventricular overdrive pacing or DC countershock. All these patients had a trial of medical therapy with amiodarone (10 patients) or sotalol (4 patients) and a further electrophysiological study after an appropriate in-hospital loading period. All patients had inducible hemodynamically significant ventricular tachycardia at the repeat electrophysiological study. One patient who had recurrent ventricular tachycardia and had discontinued amiodarone for reasons of pulmonary toxicity had reproducibly pace-terminable ventricular tachycardia, and it was decided to implant a tiered-therapy NTL ICD providing antitachycardia pacing with back-up cardioversion/defibrillation. NTL ICDs were implanted in all 23 cases attempted. Thirteen patients received devices under clinical trial, and 10 received market-released devices. General anesthesia was administered in the EP laboratory in 22 cases, and deep sedation was used in one elderly patient. The mean total time in the EP laboratory was 254±68 minutes (range, 150 to 375 minutes), with 104±42 minutes for anesthetic and other preparation, 159±45 minutes for device implantation, and 8.7±5 minutes (3 to 25 minutes) of fluoroscopy required for positioning of transvenous and subcutaneous lead systems. Implant times showed a significant improvement when the first 10 cases (188±44 minutes) were compared with the last 10 in the series (124±44 minutes, P<.01). The mean DFT was 17±5 J (5 to 25 J). Seven patients received a CPI Ventak (6 Ventak PRx, 1 Ventak P, 1 Ventak P2) with the CPI Endotak lead and a subcutaneous patch (1 patient) or array (4 patients). Six patients received an Intermedics Res-Q with a bipolar active fixation lead and subcutaneous patch. Seven patients received a Ventritex Cadence with a CPI Endotak lead. Three patients received a Medtronic PCD, one with a CPI Endotak lead and subcutaneous array, one with a tripolar active fixation electrode and two subcutaneous patches (placed in the left axilla and left infraclavicular region), and one with a tripolar right ventricular lead and superior vena cava coil. Twentyone patients had transvenous leads inserted on the left side and 2 on the right. Both right-sided leads required placement of a left axillary subcutaneous patch, such that the endocardial lead was tunneled to an abdominal generator pocket to the right of the midline, with tunneling of the subcutaneous patch lead down below the costal margin, then across the midline, to the right-sided generator pocket. Details of patient num- left common jugular venous trunk. The right subclavian vein was safely cannulated after contrast venography had confirmed its presence and location. In this case, the Endotak lead was positioned at the right ventricular apex and tunneled to a right-of-midline abdominal pocket, and a subcutaneous patch electrode was placed in the left axilla and tunneled downward and across the midline to the abdominal pocket. One patient, who had been on bed rest for 6 days before CPI Ventak PRx/Endotak lead/patch implantation, developed an acute minor pulmonary embolism 12 hours later. Intravenous heparin led to moderate bruising in and around the pulse generator pocket. This was managed conservatively with no sequelae.
Two patients with severely impaired left ventricular function (left ventricular ejection fraction of <20%), related to coronary artery disease, decompensated after defibrillation testing, with hypotension and hypoxia and an acute elevation of pulmonary capillary wedge pressure. Both patients required intensive therapy with vasodilators, diuretics, and intravenous inotropic agents; they remained intubated, received continuing positive-pressure ventilation overnight, and were successfully extubated the following day. These patients were subsequently discharged on postoperative day 6 and were in New York Heart Association functional class II at follow-up at 4 and 25 weeks.
In all patients, the NTL ICD system satisfactorily defibrillated ventricular fibrillation at the predischarge device check with 29±5 J. The mean time to hospital discharge after the implant was 5.1±3.6 days. After 12.4± 9 weeks of follow-up, all devices were functioning satisfactorily, and there had been no late complications. Ten patients received antitachycardia pacing therapy for ventricular tachycardia, which was successful in 7. Three patients received high-voltage shocks, which appear to have been appropriate in all cases, on the basis of therapy history data available from telemetry of the device and symptoms before device discharge.
Discussion
This report demonstrates that a successful program of NTL cardioverter/defibrillator implants can be initiated in an EP laboratory by electrophysiologists alone with a high level of success and minimal complications, provided that adequate facilities and expertise are available.
At present, the size of the ICD capacitors and batteries required to charge them repeatedly places miniaturization constraints on ICD generators. In the United States, smaller ICDs have a limited availability. Even with these smaller devices, which have been implanted in larger numbers in Europe, however, a substantial proportion (-40%) still need to be placed in the abdomen by use of tunneling techniques. Although a large series of pectoral "unipolar" NTL ICD systems has been tested in the United States2 before a conventional implant, there are as yet no data on these new devices chronically implanted. Reports do exist of patients receiving "conventional" sized (110 to 150 cm2) devices in the pectoral region,3 but usually the patient has been uncommonly large, rather than the device being comfortably small. In another US series of pectoral implants, a complex submuscular approach was needed to prevent generator migration, and two incisions were still required for implantation, one below the clavicle and a second under the breast. The complication rate in this series was 22%. There was no mortality, and there were no infections. In four of five cases, the complication could be related to general risks rather than the location of implantation or implant personnel. These were a pneumothorax with a subclavian venous puncture, the risk of pulmonary embolism during prolonged bed rest in hospital in the setting of cardiac failure, and hemodynamic deterioration related to DFT testing in high-risk patients with very poor left ventricular function. One complication (4%) could potentially be related specifically to electrophysiologist NTL ICD implantation. This was a hematoma at the site of axillary patch implantation, for which conservative management led to a satisfactory outcome. The incidence of patch-site hematoma was similar to that in another larger series of NTL ICD implants5 (4 of 84 patients, or 5%). In that series, however, all 80 of 84 patients successfully implanted (95%) required subcutaneous patch placement. Furthermore, the overall complication rate was higher, with 18 of 84 patients (21%) having complications directly related to the implant procedure.5 One significant complication commonly reported in NTL ICD implants is transvenous lead displacement, which may range from 0%4 to 10%.5 This was not encountered in our early experience. We attribute our lack of lead displacements to the availability of state-of-the-art radiographic equipment. This has to be contrasted with conditions in the operating room, where fluoroscopy is frequently portable and unsophisticated and electrophysiology staff make only rare appearances.
The rate of complications compares favorably with other reported series5 and with the results of epicardial ICD implants.6 One series of epicardial ICD implants reported an ICD operative mortality of 3.1% for patients also undergoing concomitant cardiac surgery and 4% for thoracotomy ICD implant alone. 6 We and others5 observed no early mortality associated with implantation despite attempting the procedure in relatively high-risk patients, a number of whom had a history of cardiac failure and poor left ventricular function. Despite the small numbers in this series, the lack of early mortality so far and the low morbidity directly attributable to the NTL ICD implant has been reassuring, and we attribute it to the availability of high-quality equipment and familiarity of implanting electrophysiologists with laboratory surroundings and personnel. The reasons for a lower mortality with NTL versus epicardial ICD implantation cannot be clarified without randomized data to exclude differences in patient populations. However, one observation made by Bardy5 and confirmed in this series is the lack of a clustering of ventricular arrhythmia episodes around the time of operation, which has been reported elsewhere.7 It is possible that damage to epicardial sympathetic nerves with epicardial defibrillation may result in inhomogeneity of sympathetic innervation, dispersion of refractoriness, and proarrhythmia, as recently demonstrated in laboratory animals.8
The combined considerations of NTL ICD hardware complexity; electrophysiologist, nursing, and support staff training; and time required for implantation suggest that a level of certification and capitalization are needed for a successful NTL ICD implant program. We anticipate that new NTL ICD programs will be expected to meet nationally agreed-upon professional guidelines for training and facilities,9 updated to meet the challenge of new technologies.
